Could Ceramides Become the New Cholesterol?

The Mayo Clinic recently introduced a diagnostic test that quantifies plasma ceramides in order to identify patients at risk of major adverse cardiac events. By comparing recent discoveries about these biomarker ceramides with the exhaustive body of literature surrounding cholesterol, Summers aims to highlight important advances and critically needed areas of investigation on this exciting class of bioactive lipids. Scott Summers evaluates the current status of research on ceramides, a lipid implicated in cardiometabolic disorders that shows intriguing parallels with cholesterol.